Nabaxor (Rivaroxaban)

Rivaroxaban, the active ingredient in Nabaxor, is a Direct Factor Xa Inhibitor presented as an oral tablet for oral use. It is employed to reduce the risk of stroke and systemic embolism in patients with non‑valvular atrial fibrillation and to treat or prevent deep‑vein thrombosis and pulmonary embolism.

GNH USA supplies Nabaxor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Rivaroxaban is indicated for several thromboembolic conditions affecting the cardiovascular and venous systems.

- Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep‑vein thrombosis (DVT): treats acute clot formation and facilitates resolution. - Pulmonary embolism (PE): manages acute embolic events and supports recovery. - Recurrent DVT/PE: prevents further thrombotic episodes after initial treatment. - Post‑operative prophylaxis after hip or knee replacement: lowers incidence of postoperative DVT.

Rivaroxaban may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bruising or minor bleeding at sites of injury. - Nosebleeds or gum bleeding. - Headache. - Gastrointestinal upset such as nausea or diarrhea.

Serious or Rare Side Effects: - Intracranial hemorrhage. - Major gastrointestinal bleeding. - Spinal or epidural hematoma, especially after neuraxial procedures. - Severe allergic reactions including anaphylaxis. - Elevated liver enzymes or hepatic dysfunction. - Thrombocytopenia.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor appropriately.

- Renal function assessment: adjust therapy in severe impairment. - Bleeding risk evaluation: avoid in patients with active uncontrolled bleeding. - Concomitant antiplatelet therapy: monitor for additive bleeding risk. - Surgical or invasive procedures: discontinue according to recommended timing. - Pregnancy and lactation: use only if potential benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Rivaroxaban interacts with several drug classes; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce anticoagulant effect. - Concurrent use with other anticoagulants (e.g., warfarin, heparin): markedly heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): additive bleeding potential. - Non‑steroidal anti‑inflammatory drugs (e.g., ibuprofen, naproxen): increase gastrointestinal bleeding risk. - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline): possible enhancement of bleeding.